Nuveen’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-251,460
| Closed | -$18.1M | – | 3280 |
|
|
2025
Q4 | $18.1M | Buy |
251,460
+39,168
| +18% | +$2.53M | ﹤0.01% | 1206 |
|
|
2025
Q3 | $9.25M | Sell |
212,292
-57,122
| -21% | -$2.31M | ﹤0.01% | 1597 |
|
|
2025
Q2 | $7.65M | Sell |
269,414
-161,797
| -38% | -$4.82M | ﹤0.01% | 1667 |
|
|
2025
Q1 | $12.7M | Buy |
431,211
+78,713
| +22% | +$2.45M | ﹤0.01% | 1408 |
|
|
2024
Q4 | $10.3M | Sell |
352,498
-706,062
| -67% | -$29.5M | ﹤0.01% | 1588 |
|
|
2024
Q3 | $48.6M | Sell |
1,058,560
-150,140
| -12% | -$6.52M | 0.01% | 677 |
|
|
2024
Q2 | $49.4M | Buy |
1,208,700
+134,841
| +13% | +$3.87M | 0.01% | 626 |
|
|
2024
Q1 | $27.4M | Buy |
1,073,859
+583,265
| +119% | +$9.14M | 0.01% | 973 |
|
|
2023
Q4 | $4.44M | Buy |
490,594
+279,718
| +133% | +$1.87M | ﹤0.01% | 2048 |
|
|
2023
Q3 | $1.35M | Sell |
210,876
-1,664
| -0.8% | -$14.3K | ﹤0.01% | 2454 |
|
|
2023
Q2 | $2.36M | Buy |
212,540
+6,103
| +3% | +$76.6K | ﹤0.01% | 2272 |
|
|
2023
Q1 | $3.17M | Buy |
206,437
+28,617
| +16% | +$630K | ﹤0.01% | 2139 |
|
|
2022
Q4 | $3.95M | Buy |
177,820
+35,255
| +25% | +$526K | ﹤0.01% | 2050 |
|
|
2022
Q3 | $2.33M | Sell |
142,565
-40,897
| -22% | -$782K | ﹤0.01% | 2323 |
|
|
2022
Q2 | $2.67M | Buy |
183,462
+70,506
| +62% | +$1.05M | ﹤0.01% | 2291 |
|
|
2022
Q1 | $1.99M | Sell |
112,956
-1,238
| -1% | -$21K | ﹤0.01% | 2508 |
|
|
2021
Q4 | $2.69M | Sell |
114,194
-7,873
| -6% | -$188K | ﹤0.01% | 2422 |
|
|
2021
Q3 | $2.92M | Buy |
122,067
+4,007
| +3% | +$87.1K | ﹤0.01% | 2497 |
|
|
2021
Q2 | $2.92M | Buy |
118,060
+21,804
| +23% | +$507K | ﹤0.01% | 2534 |
|
|
2021
Q1 | $2.1M | Buy |
96,256
+31,104
| +48% | +$761K | ﹤0.01% | 2591 |
|
|
2020
Q4 | $1.66M | Buy |
65,152
+211
| +0.3% | +$6.15K | ﹤0.01% | 2596 |
|
|
2020
Q3 | $1.83M | Buy |
+64,941
| New | +$1.88M | ﹤0.01% | 2427 |
|
Other funds holding RNAM
Nuveen's RNAM Position: Q1 2026 in Review
Nuveen sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 251,460 shares — an estimated $18.1M sold.
Nuveen first reported a position in RNAM in Q3 2020 and held it in 22 quarters. The position peaked at $49.4M in Q2 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Nuveen reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Nuveen sold 251,460 Avidity Biosciences shares in Q1 2026, an estimated $18.1M.
- Nuveen first reported a position in Avidity Biosciences in Q3 2020 and held it in 22 quarters.
- Nuveen's Avidity Biosciences position peaked at $49.4M in Q2 2024.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.